betamethason sandoz zalf 1 mg/g, hydrofobe zalf
sandoz b.v. - betamethasonvaleraat; - zalf - betamethasone
betamethason bmodesto emulsie voor cutaan gebruik 1 mg/g
bmodesto b.v. minervaweg 2 8239 dl lelystad - betamethasonvaleraat samenstelling overeenkomend met ; betamethason - emulsie voor cutaan gebruik - cetostearylalcohol ; citroenzuur 1-water (e 330) ; glycerol (e 422) ; isopropylalcohol ; macrogolcetostearylether ; methylparahydroxybenzoaat (e 218) ; paraffine, vloeibaar (e905) ; trinatriumcitraat 2-water (e 331) ; water, gezuiverd ; xanthaangom (e 415) - betamethasone
betamethasone dipropionate- betamethasone dipropionate ointment
warrick pharmaceuticals corporation - betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - ointment - 0.5 mg in 1 g - augmented betamethasone dipropionate ointment is indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. augmented betamethasone dipropionate ointment is contraindicated in patients who are hypersensitive to betamethasone dipropionate, to other corticosteroids, or to any ingredient in this preparation.
readysharp betamethasone- betamethasone sodium phosphate and betamethasone acetate injection, suspension
terrain pharmaceuticals - betamethasone acetate (unii: ti05ao53l7) (betamethasone - unii:9842x06q6m), betamethasone sodium phosphate (unii: 7bk02scl3w) (betamethasone - unii:9842x06q6m) - betamethasone acetate 3 mg in 1 ml - when oral therapy is not feasible, the intramuscular use of betamethasone sodium phosphate and betamethasone acetate injectable suspension is indicated as follows: allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. dermatologic diseases bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (stevens-johnson syndrome). endocrine disorders congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular
calcipotriol/betamethason teva 50 microgram/g + 0,5 mg/g, zalf
teva nederland b.v. swensweg 5 2031 ga haarlem - betamethasondipropionaat 0,6 mg/g samenstelling overeenkomend met ; betamethason 0,5 mg/g ; calcipotriol 50 µg/g - zalf - butylhydroxytolueen (e 321) ; paraffine, vloeibaar (e905) ; paraffine, zacht (e 905) ; polyoxypropyleen-15-stearylether, - calcipotriol, combinations
fusidinezuur/betamethasone dermapharm 20 mg/g - 1 mg/g crème
dermapharm ag - fusidinezuurhemihydraat 20,4 mg/g - eq. fusidinezuur 20 mg/g; betamethasonvaleraat 1,214 mg/g - eq. betamethason 1 mg/g - crème - 20 mg/g - 1 mg/g - fusidinezuurhemihydraat 20.4 mg; betamethasonvaleraat 1.214 mg/g - betamethasone and antibiotics
betamethason acis crinale
acis arzneimittel gmbh (8087957) - betamethasonvalerat (ph.eur.) - lösung zur anwendung auf der haut - teil 1 - lösung zur anwendung auf der haut; betamethasonvalerat (ph.eur.) (03381) 1,22 milligramm
betamethason exeltis 1 mg/g lösung zur anwendung auf der haut (kopfhaut)
exeltis germany gmbh (8128254) - betamethasonvalerat (ph.eur.) - lösung zur anwendung auf der haut (kopfhaut) - teil 1 - lösung zur anwendung auf der haut (kopfhaut); betamethasonvalerat (ph.eur.) (03381) 1,22 milligramm
calcipotriol/betamethason dermapharm 50 mikrogramm/g + 0,5 mg/g salbe
dermapharm ag - betamethason dipropionat; calcipotriol monohydrat -
betamethasone schering-plough 2 mg, comprimé dispersible sécable
schering plough - bétaméthasone - comprimé - 2 mg - composition pour un comprimé > bétaméthasone : 2 mg